Serevent Asthma Safety Signal Is Good News For Advair, GSK Says
Executive Summary
Adverse event outcomes from a Serevent safety study could help GlaxoSmithKline in one of its key messages for Advair, CEO J.P. Garnier told analysts in New York City Feb. 13
You may also be interested in...
GSK’s Advair, Serevent Add “Black Box” On Rare Asthma-Related Deaths
GlaxoSmithKline has revised labeling for Advair and Serevent to include "black box" warnings on an increased risk of asthma-related deaths in patients taking salmeterol
GSK’s Advair, Serevent Add “Black Box” On Rare Asthma-Related Deaths
GlaxoSmithKline has revised labeling for Advair and Serevent to include "black box" warnings on an increased risk of asthma-related deaths in patients taking salmeterol
GSK Serevent Safety Label Change Coming Soon; Will Advair Be Affected?
GlaxoSmithKline will meet with FDA to discuss the interim results from the company's halted Serevent safety study and determine whether the information should be added to product labeling